144 research outputs found
Impatto clinico degli anticorpi anti-endotelio (AECA) nel trapianto di rene e e di pancreas
Il ruolo dell’autoimmunità , in aggiunta a quello ben noto dell’alloimmunità , nel condizionare la sopravvivenza del trapianto di organo solido, è argomento di recente interesse scientifico.
Gli anticorpi anti-endotelio (AECA) sono stati associati alla probabilità di rigetto in seguito a trapianto. Purtroppo la mancanza di test economici standardizzati ed a basso costo ha impedito l’effettuazione routinaria di questo screening.
La tecnica di immunofluorescenza indiretta (TiterplaneTM) su linee di cellule endoteliali della vena ombelicale umana (HUVEC) mira a colmare questa mancanza.
Lo studio, in merito a questo argomento, è iniziato analizzando 168 trapianti di pancreas e rene effettuati presso il Centro Trapianti di Pancreas e Rene dell’Azienda Ospedaliera Universitaria Pisana. Dei pazienti analizzati 40 sono stati esclusi dallo studio per follow-up inferiore a 6 mesi, o
di esecuzione di procedere aferetiche peri trapianto.
Nello studio è stato usato un singolo lotto di TiterplaneTM le cui HUVEC sono state tipizzate in modo da poter discriminare gli AECA dagli anticorpi anti-HLA.
Dei 128 pazienti clinica arruolati, 17 sono risultati AECA positivi giĂ prima del trapianto (AECA pre-,+), di questi 8 hanno mostrato negativizzazione per gli AECA in tempi diversi nel periodo post-trapianto.
I pazienti che hanno mostrato AECA pre+ nel trapianto di pancreas presentano maggior rischio di rigetti cellulo-mediati ripetuti, che aumenta nei pazienti AECA+ post-trapianto. Non c’è correlazione, invece, tra la presenza di AECA pre+ ed il rigetto di rene.
Il risultato del presente studio dimostra quindi che la presenza di AECA (nel periodo pre o post trapianto) non è rilevante nel trapianto di rene, mentre sembra meritare un più approfondito studio la relazione con il rigetto di pancreas
Plan de manejo ambiental para mitigar los impactos generados por explotacion minera en el municipio de NechĂ en el Bajo Cauca - RegiĂłn de La Mojana
Trabajo de InvestigaciónEsta investigación propone un Plan de Manejo Ambiental enfocado a la explotación minera, especialmente dirigido al municipio de Nechà – Antioquia (Colombia), lo anterior debido a los problemas y fuertes impactos ambientales y sociales, que se han visto con el pasar del tiempo debido al mal manejo de los procesos necesarios para tal fin.INTRODUCCIÓN
1. ANTECEDENTES
2. PLANTEAMIENTO Y FORMULACION DEL PROBLEMA
3. OBJETIVOS
4. MARCO DE REFERECIA TEORICO
5. MARCO DE REFERECIA CONCEPTUAL
6. CARACTERIZACION DEL TERRITORIO
7. ESTUDIO DE IMPACTO AMBIENTAL E IDENTIFICACION DE PROBLEMAS GENERADOS POR LA EXPLOTACION MINERA
8. DISEĂ‘O PLAN DE MANEJO AMBIENTAL 9. CONCLUSIONES Y RECOMENDACIONES
10. BIBLIOGRAFIAPregradoIngeniero Civi
Seizure progression is slowed by enhancing neurosteroid availability in the brain of epileptic rats
Trilostane is a 3β-hydroxysteroid
dehydrogenase/Δ5-4
isomerase inhibitor able to
produce a manyfold increase in brain levels of various neurosteroids, including
allopregnanolone. We previously found that treatment with trilostane can slow
down epileptogenesis in the kainic acid (KA) model of temporal lobe epilepsy. It
is unknown whether trilostane may have a similar effect on the progression of
epilepsy severity, as observed in KA-treated
rats. Consequently, we investigated
the effects of trilostane (50 mg/kg/day, 1 week) in epileptic rats, given 64 days
after KA administration. Seizures were monitored by video-electrocorticographic
recordings before and during the treatment with trilostane or vehicle (sesame
oil), and neurosteroid levels were measured in serum and cerebral tissue using
liquid chromatography–electrospray tandem mass spectrometry after treatment.
Pregnenolone sulfate, pregnenolone, progesterone, 5α-dihydroprogesterone,
and allopregnanolone peripheral levels were massively increased by trilostane.
With the only exception of hippocampal pregnenolone sulfate, the other neurosteroids
augmented in both the neocortex and hippocampus. Only pregnanolone
levels were not upregulated by trilostane. As expected, a significant increase in
the seizure occurrence was observed in rats receiving the vehicle, but not in the
trilostane group. This suggests that the increased availability of neurosteroids
produced a disease-modifying
effect in the brain of epileptic rats
Status epilepticus dynamics predicts latency to spontaneous seizures in the kainic acid model
(TLE), a common neurologic disorder characterized by spontaneous recurrent seizures (SRSs).
However, the relationship between SE and TLE is still incompletely characterized. For this
reason, in a model of TLE we evaluated the lesion extent and the onset of SRSs to determine if
they were influenced by the SE dynamics. Methods: Sixty-two adult male Sprague-Dawley rats
were implanted for video-electrocorticographic (v-ECoG) monitoring and intraperitoneally
treated with saline or kainic acid (KA, 15 mg/kg) at 8 weeks of age. v-ECoG recordings were
obtained during SE, in the following 9 weeks, and assessed by amplitude or power band
spectrum. Rats were euthanized 3 or 64 days after SE to evaluate the lesion. Results: SE
lasted about 10 h during which the mean duration of convulsive seizures (CSs) increased
from 39 s, at 30 min, to 603 s at 4 h. The gamma power peaked 30 min after the SE onset
and its peak was correlated (r²=0.13, p=0.042) with the overall SE duration. Subsequently, the
gamma power was reduced under the baseline until the end of SE. The theta power increased
at approximately 150% of basal levels 3 h after KA injection, but it went back to basal levels
with the full development of CSs. Interestingly, the timing of the first SRS in chronic epilepsy
was correlated with the latency to develop the first CS with loss of posture during SE (r²=0.60,
p<0.001). Additionally, the overall duration of CSs observed during SE was related to the
number of damaged brain regions (r²=0.60, p=0.005), but it did not influence the timing
of the first SRS in chronic epilepsy. Conclusion: Overall, our results show that the onset of
chronic epilepsy is modulated by SE dynamics, whereas brain damage is related to prolonged
convulsions in SE
Electrographic changes accompanying recurrent seizures under ketogenic diet treatment.
The ketogenic diet (KD) is increasingly used to treat epilepsy refractory to antiepileptic
drugs and other neurological disorders. In animal models, the KD was found to increase the
threshold to seizures induced by different convulsive stimulations. However, in models in which
suprathreshold stimuli were used, a paradoxical seizure worsening was consistently observed in
KD-fed animals. To better define this phenomenon, we characterized the electrographic response to
seizures induced in mice which were treated with the KD, and then corneally stimulated at 6-Hz in
four different sessions. We also evaluated the electroencephalogram (EEG) in three patients in
which the KD was associated with a paradoxical worsening of epileptic seizures. Although seizures
were initially less severe, a remarkable prolongation of the electrographic response was observed
in mice receiving the KD from the second session of 6-Hz corneal stimulation and onwards. The
EEG was also markedly altered in the presence of progressive seizure aggravation observed in
children treated with the KD, specifically one affected by Lennox\u2013Gastaut syndrome and two by
type I lissencephaly. These results suggest that when seizures are induced or recur because of
resistance to therapeutic interventions, the KD may change the EEG by potentiating the
electrographic epileptic activity
BV-2 Microglial Cells Respond to Rotenone Toxic Insult by Modifying Pregnenolone, 5alpha-Dihydroprogesterone and Pregnanolone Level
Neuroinflammation, whose distinctive sign is the activation of microglia, is supposed
to play a key role in the development and progression of neurodegenerative diseases. The aim of
this investigation was to determine levels of neurosteroids produced by resting and injured BV-2
microglial cells. BV-2 cells were exposed to increasing concentrations of rotenone to progressively
reduce their viability by increasing reactive oxygen species (ROS) production. BV-2 cell viability
was significantly reduced 24, 48 and 72 h after rotenone (50–1000 nM) exposure. Concomitantly,
rotenone (50–100 nM) determined a dose-independent augmentation of ROS production. Then,
BV-2 cells were exposed to a single, threshold dose of rotenone (75 nM) to evaluate the
overtime release of neurosteroids. In particular, pregnenolone, pregnenolone sulfate, progesterone,
5alpha-dihydroprogesterone (5-DHP), allopregnanolone, and pregnanolone, were quantified in the
culture medium by liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis.
BV-2 cells synthesized all the investigated neurosteroids and, after exposure to rotenone, 5DHP and
pregnanolone production was remarkably increased. In conclusion, we found that BV-2 cells not only
synthesize several neurosteroids, but further increase this production following oxidative damage.
Pregnanolone and 5alpha-DHP may play a role in modifying the progression of neuroinflammation in
neurodegenerative diseases
Protective but Not Anticonvulsant Effects of Ghrelin and JMV-1843 in the Pilocarpine Model of Status epilepticus.
In models of status epilepticus ghrelin displays neuroprotective effects mediated by the growth hormone secretagogue-receptor 1a (GHS-R1a). This activity may be explained by anticonvulsant properties that, however, are controversial. We further investigated neuroprotection and the effects on seizures by comparing ghrelin with a more effective GHS-R1a agonist, JMV-1843. Rats were treated either with ghrelin, JMV-1843 or saline 10 min before pilocarpine, which was used to induce status epilepticus. Status epilepticus, developed in all rats, was attenuated by diazepam. No differences were observed among the various groups in the characteristics of pilocarpine-induced seizures. In saline group the area of lesion, characterized by lack of glial fibrillary acidic protein immunoreactivity, was of 0.45\ub10.07 mm2 in the hippocampal stratum lacunosum-moleculare, and was accompanied by upregulation of laminin immunostaining, and by increased endothelin-1 expression. Both ghrelin (P<0.05) and JMV-1843 (P<0.01) were able to reduce the area of loss in glial fibrillary acidic protein immunostaining. In addition, JMV-1843 counteracted (P<0.05) the changes in laminin and endothelin-1 expression, both increased in ghrelin-treated rats. JMV-1843 was able to ameliorate neuronal survival in the hilus of dentate gyrus and medial entorhinal cortex layer III (P<0.05 vs saline and ghrelin groups). These results demonstrate diverse protective effects of growth hormone secretagogues in rats exposed to status epilepticus
Involvement of PPAR\u3b3 in the anticonvulsant activity of EP-80317, a ghrelin receptor antagonist
Ghrelin, des-acyl ghrelin and other related peptides possess anticonvulsant activities. Although ghrelin and cognate peptides were shown to physiologically regulate only the ghrelin receptor, some of them were pharmacologically proved to activate the peroxisome proliferator-activated receptor gamma (PPAR\u3b3) through stimulation of the scavenger receptor CD36 in macrophages. In our study, we challenged the hypothesis that PPAR\u3b3 could be involved in the anticonvulsant effects of EP-80317, a ghrelin receptor antagonist. For this purpose, we used the PPAR\u3b3 antagonist GW9662 to evaluate the modulation of EP-80317 anticonvulsant properties in two different models. Firstly, the anticonvulsant effects of EP-80317 were studied in rats treated with pilocarpine to induce status epilepticus (SE). Secondly, the anticonvulsant activity of EP-80317 was ascertained in the repeated 6-Hz corneal stimulation model in mice. Behavioral and video electrocorticographic (ECoG) analyses were performed in both models. We also characterized levels of immunoreactivity for PPAR\u3b3 in the hippocampus of 6-Hz corneally stimulated mice. EP-80317 predictably antagonized seizures in both models. Pre-treatment with GW9662 counteracted almost all EP-80317 effects both in mice and rats. Only the effects of EP-80317 on power spectra of ECoGs recorded during repeated 6-Hz corneal stimulation were practically unaffected by GW9662 administration. Moreover, GW9662 alone produced a decrease in the latency of tonic-clonic seizures and accelerated the onset of SE in rats. Finally, in the hippocampus of mice treated with EP-80317 we found increased levels of PPAR\u3b3 immunoreactivity. Overall, these results support the hypothesis that PPAR\u3b3 is able to modulate seizures and mediates the anticonvulsant effects of EP-80317
Progressive Seizure Aggravation in the Repeated 6-Hz Corneal Stimulation Model Is Accompanied by Marked Increase in Hippocampal p-ERK1/2 Immunoreactivity in Neurons
The 6-Hz corneal stimulation test is used to screen novel antiepileptic molecules to overcome the problem of drug refractoriness. Although recognized as a standard test, it has been evaluated only recently in the attempt to characterize the putative neuronal networks involved in seizures caused by corneal stimulation. In particular, by recording from the CA1 region we previously established that the hippocampus participates to propagation of seizure activity. However, these findings were not corroborated by using markers of neuronal activation such as FosB/ΔFosB antigens. In view of this discrepancy, we performed new experiments to characterize the changes in levels of phosphorylated extracellular signal-regulated kinases1/2 (p-ERK1/2), which are also used as markers of neuronal activation. To this aim, mice underwent corneal stimulation up to three different times, in three sessions separated by an interval of 3 days. To characterize a group in which seizures could be prevented by pharmacological treatment, we also considered pretreatment with the ghrelin receptor antagonist EP-80317 (330 μg/kg). Control mice were sham-treated. Video electrocorticographic (ECoG) recordings were obtained from mice belonging to each group of treatment. Animals were finally used to characterize the immunoreactivity for FosB/ΔFosB and p-ERK1/2 in the hippocampus. As previously shown, FosB/ΔFosB levels were highly increased throughout the hippocampus by the first induced seizure but, in spite of the progressively increased seizure severity, they were restored to control levels after the third stimulation. At variance, corneal stimulation caused a progressive increase in p-ERK1/2 immunoreactivity all over the hippocampus, especially in CA1, peaking in the third session. Predictably, EP-80317 administration reduced both duration and severity of seizures, prevented the increase in FosB/ΔFosB levels in the first session, and partially counteracted the increase in p-ERK1/2 levels in the third session. The vast majority of p-ERK1/2 immunopositive cells were co-labeled with FosB/ΔFosB antibodies, suggesting the existence of a relationship between the investigated markers in a subpopulation of neurons activated by seizures. These findings suggest that p-ERK1/2 are useful markers to define the aggravation of seizures and the response to anticonvulsant treatments. In particular, p-ERK1/2 expression clearly identified the involvement of hippocampal regions during seizure aggravation in the 6-Hz model
Ghrelin plasma levels after 1 year of ketogenic diet in children with refractory epilepsy
The ketogenic diet (KD) is a high-fat, low carbohydrate nutritional treatment adopted in several countries for refractory epilepsy. However, the use of KD is limited by adverse events including growth retardation. In a previous investigation, we demonstrated that ghrelin is reduced in children maintained on KD for 3 months. As ghrelin regulates growth hormone (GH) secretion, it can be hypothesized that growth retardation depends on the reduced ghrelin availability. To assess this hypothesis, in this study we evaluate ghrelin and growth during 1 year of KD. We examined a small cohort of 6 children (2 males and 4 females, age range 3\u201310.4 years) affected by refractory epilepsy, who received the KD as add-on treatment. All patients were on drug polytherapy. Endpoints of the study were: (i) ghrelin plasma levels at 0, 15, 30, 90, and 365 days from KD onset, (ii) growth, and (iii) seizure control by ketogenesis. Ghrelin levels were 1253 and 1247% of basal levels, respectively, at 90 and 365 days (P < 0.05 for both). Mean height index z scores were reduced, but not significantly, by comparing basal values with those at the end of observation. Instead, body mass index z scores slightly increased. Ketosis induced by the KD was within 2\u20135 mmol/L and satisfactorily reduced the seizure frequency (>50%) in all patients. We show that ghrelin plasma levels are consistently reduced in children with refractory epilepsy and maintained on the KD. This change was associated with low growth indexes in the majority of patients
- …